Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 1,003

The DOI matches its Crossref record; 206 of the 206 references it cites were found in a registry or an index.

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Benson, Al B., D’Angelica, Michael I., Abbott, Daniel E., Anaya, Daniel A., Anders, Robert, Are, Chandrakanth, Bachini, Melinda, Borad, Mitesh, Brown, Daniel, Burgoyne, Adam, Chahal, Prabhleen, Chang, Daniel T., Cloyd, Jordan, Covey, Anne M., Glazer, Evan S., Goyal, Lipika, Hawkins, William G., Iyer, Renuka, Jacob, Rojymon, Kelley, R. Kate, Kim, Robin, Levine, Matthew, Palta, Manisha, Park, James O., Raman, Steven, Reddy, Sanjay, Sahai, Vaibhav, Schefter, Tracey, Singh, Gagandeep, Stein, Stacey, Vauthey, Jean-Nicolas, Venook, Alan P., Yopp, Adam, McMillian, Nicole R., Hochstetler, Cindy, Darlow, Susan D.·2021·Journal of the National Comprehensive Cancer Network

Abstract

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.6004/jnccn.2021.0022

Cites

206 of 206 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 206 references

Cited by

See all 1,003

Metadata

Authors
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., Chahal, P., Chang, D. T., Cloyd, J., Covey, A. M., Glazer, E. S., Goyal, L., Hawkins, W. G., Iyer, R., Jacob, R., Kelley, R. K., Kim, R., Levine, M., Palta, M., Park, J. O., Raman, S., Reddy, S., Sahai, V., Schefter, T., Singh, G., Stein, S., Vauthey, J.-N., Venook, A. P., Yopp, A., McMillian, N. R., Hochstetler, C., & Darlow, S. D.
Venue
Journal of the National Comprehensive Cancer Network
Published
2021-05
Volume
19
Issue
5
Pages
541-565
ISSN
  • 1540-1405 (ISSN-L)
  • 1540-1413
OpenAlex
W3165133969
Cited by
1,003
References
206
FWCI
86.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. https://app.cochat.ai/papers/10.6004/jnccn.2021.0022
The paper
Benson, A. B., D’Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C., Bachini, M., Borad, M., Brown, D., Burgoyne, A., Chahal, P., Chang, D. T., Cloyd, J., Covey, A. M., Glazer, E. S., Goyal, L., Hawkins, W. G., Iyer, R., Jacob, R., . . . Darlow, S. D. (2021). Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2021.0022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.